University of Kentucky Center for Cancer Metabolism

肯塔基大学癌症代谢中心

• 批准号: 10573133
• 负责人: DARET K ST CLAIR
• 金额: $ 228.97万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10573133
• 关键词: Address; Applications Grants; Area; Basic Science; Biochemistry; Bioinformatics; Biology; Biometry; Cancer Center; Cell Survival; Centers of Research Excellence; Clinical; Clinical Trials; Collaborations; Core Facility; Coupled; Data; Dedications; Development; Disease; Distant Metastasis; Drug resistance; Early Diagnosis; Educational workshop; Environment; Epigenetic Process; Equipment; Extramural Activities; Faculty; Fees; Fostering; Foundations; Funding; Goals; Grant; Growth; Health; Image; Incidence; Infrastructure; Institution; Interdisciplinary Study; Intervention; Kentucky; Link; Malignant Neoplasms; Mediator; Mentors; Metabolic; Metabolic Diseases; Metabolism; Methodology; Neoplasm Metastasis; Obesity; Outcome; Oxidation-Reduction; Phase; Pilot Projects; Positioning Attribute; Productivity; Protein Array; Quality of life; Recurrence; Research; Research Personnel; Research Project Grants; Research Support; Role; Scientist; Services; Signal Transduction; System; Therapeutic; Training; Translational Research; Translations; United States National Institutes of Health; Universities; Vital capacity; animal imaging; anticancer research; base; cancer cell; cancer imaging; cancer initiation; cancer prevention; cancer therapy; career; defined contribution; early detection biomarkers; editorial; improved; in vivo; innovation; metabolomics; mortality; multidisciplinary; new technology; next generation; novel; prevent; programs; recruit; skills; success; symposium; synergism; therapeutic target; therapy resistant; tool; tumor; tumor initiation; tumor metabolism; tumorigenesis

PROJECT SUMMARY The University of Kentucky (UK) Center of Biomedical Research Excellence on Cancer and Metabolism (CCM) was established in March 2017 by a multidisciplinary team of basic and clinical scientists engaged in cutting- edge research on metabolic dysregulations in cancer, an emerging hallmark of disease responsible for tumor development, drug resistance and distant metastasis. The overarching goal of the Phase II CCM is to continue efforts to expand a thematically focused multidisciplinary infrastructure dedicated to defining the contribution of metabolism in the development and treatment of cancer and to use this novel multidisciplinary platform to develop promising project leaders with enhanced skills in an exciting new area of cancer research. With a dedicated team of mentors combining basic and clinical expertise in redox biology, cancer cell signaling, epigenetics, systems biochemistry and clinical trials, as well as core strengths in advanced metabolomics and sophisticated cancer imaging, we will accomplish this overall goal by conducting high-quality basic and translational research addressing metabolic reprogramming governing tumor initiation, metastasis, drug resistance and recurrence. This objective will be met by achieving 2 Specific Aims. Specific Aim 1 is to expand the critical mass of investigators conducting CCM thematic research. We will recruit, coach and solidify the commitment of a cadre of promising project leaders to conduct cancer and metabolism research utilizing a highly effective mentoring system and provide these scientists with cutting-edge research core facilities and services. Proposed new synergies will be developed through 4 well-crafted research projects; an Administrative Core; innovative research cores in metabolism and imaging; strong biostatistics and bioinformatics support; and collaborations with other UK research centers to facilitate the translation of basic findings in cancer metabolism into early therapeutic and/or intervention approaches. Specific Aim 2 is to advance an independent, sustainable, multidisciplinary thematic biomedical infrastructure and research program on cancer and metabolism by strengthening key scientific cores. We propose to expand the scope and capacity of these vital cores by acquiring and installing new state-of-the-art equipment, introducing new technologies and service as well as providing training sessions, workshops and symposiums. Kentucky ranks highest in rates of overall cancer incidence and mortality [1]. In Phase I, the CCM had a transformative impact in career research and retention of the next generation of scientists who address metabolic dysregulations underpinning the causal links between metabolic disorders and cancer development, a major health threat in the nation. Importantly, the Phase II application will build upon these accomplishments to propel CCM to a nationally recognized center in cancer and metabolism research that will also address the region’s critical needs.

项目摘要 肯塔基州大学（英国）癌症和代谢生物医学研究卓越中心（CCM） 由一个多学科的基础和临床科学家团队于2017年3月成立， 癌症中代谢失调的边缘研究，这是一种导致肿瘤的疾病的新标志 发展、耐药性和远处转移。《集束弹药公约》第二阶段的总体目标是继续 努力扩大以专题为重点的多学科基础设施， 代谢在癌症的发展和治疗中的作用，并利用这一新的多学科平台， 培养有前途的项目领导者，在癌症研究的一个令人兴奋的新领域增强技能。与 专业的导师团队，结合了氧化还原生物学，癌细胞信号传导， 表观遗传学、系统生物化学和临床试验，以及先进代谢组学和 先进的癌症成像，我们将通过进行高质量的基础和 转化研究解决代谢重编程控制肿瘤起始、转移、药物 抵抗和复发。这一目标将通过实现两个具体目标来实现。具体目标1：扩大 进行CCM专题研究的调查人员的临界质量。我们将招募，训练和巩固 一批有前途的项目领导人承诺利用高度的 有效的指导系统，并为这些科学家提供尖端的研究核心设施和服务。 将通过4个精心设计的研究项目发展拟议的新的协同作用; 代谢和成像方面的创新研究核心;强大的生物统计学和生物信息学支持;以及 与其他英国研究中心合作，促进癌症代谢基本发现的转化 早期治疗和/或干预方法。具体目标2是促进一个独立的、可持续的、 多学科主题生物医学基础设施和癌症和代谢研究计划， 加强核心科学研究。我们建议通过收购这些重要核心， 并安装新的最先进的设备，引进新的技术和服务，以及提供 培训班、讲习班和专题讨论会。肯塔基州的癌症发病率最高， 死亡率[1]。在第一阶段，CCM在职业研究和保留下一个方面产生了变革性的影响。 一代科学家谁解决代谢失调的基础上的因果关系之间的代谢 疾病和癌症的发展，在国家的主要健康威胁。重要的是，第二阶段应用程序将 在这些成就的基础上，推动CCM成为全国公认的癌症和代谢中心 研究也将解决该地区的关键需求。